Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biotech Licensing Often More Cost-Effective Than In-House R&D For Pharma

Executive Summary

Large pharmaceutical manufacturers are entering into more early stage licensing deals with biotechs because such deals are often more cost-effective than conducting in-house research, Bayer VP-Business Development Chris Seaton said

You may also be interested in...



GSK Says No To Early Stage Deal-Making, Citing High Likelihood Of Failure

GlaxoSmithKline's in-licensing efforts will focus on late-stage compounds due to the high risk of earlier stage deals, CEO J.P. Garnier said Feb. 8

Licensing An Adjunct To In-House R&D, Not A Substitute – AstraZeneca Exec

AstraZeneca views licensing and acquisitions as an add-on to, rather than a replacement for, internal research & development, Exec Director-Development John Patterson said Sept. 19

Licensing An Adjunct To In-House R&D, Not A Substitute – AstraZeneca Exec

AstraZeneca views licensing and acquisitions as an add-on to, rather than a replacement for, internal research & development, Exec Director-Development John Patterson said Sept. 19

Related Content

UsernamePublicRestriction

Register

PS047103

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel